Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer

OBJECTIVE: The KEYNOTE‐590 trial showed that individuals with advanced esophageal cancer who received Pembrolizumab in combination with chemotherapy as a first‐line regimen achieved a significant extension of survival. However, this treatment option increases the financial burden on patients and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhuo‐Miao, Xu, Zhe, Wang, Hao‐Lun, Wang, Ying‐Yuan, Chen, Ze‐Chang, Zhou, Qin, Li, Xiang‐Ping, Zhang, Ying‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028044/
https://www.ncbi.nlm.nih.gov/pubmed/36271484
http://dx.doi.org/10.1002/cam4.5350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028044/
https://www.ncbi.nlm.nih.gov/pubmed/36271484
http://dx.doi.org/10.1002/cam4.5350

Ejemplares similares